Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Filings indexed 1,392 across all filing types
Latest filing 2014-11-10 Regulatory Filings
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2014
Regulatory Filings
2014-11-10 English
Major Shareholding Notification 2014
Major Shareholding Notification
2014-11-07 English
10-Q
Interim / Quarterly Report Q3 2014
2014-10-31 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 27, 2014, reporting the company's financial results for the three and nine months ended September 30, 2014. It specifically mentions that it includes a press release announcing these financial results. The document is relatively short (3184 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis itself. According to the rules, initial announcements of quarterly or periodical financial results (key highlights only) are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release.
2014-10-27 English
PRIMARY DOCUMENT
Director's Dealing
2014-10-16 English
PRIMARY DOCUMENT
Director's Dealing
2014-10-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.